Global /India /Healthcare /Drug Manufacturers - General /AARTIDRUGS
chevron_leftBack
Aarti Drugs Ltd. logo

Aarti Drugs Ltd.

AARTIDRUGS
NSE: AARTIDRUGS Delayed
376.30INR 0.8%
3.99 USD
As of 20 June 2026, Aarti Drugs Ltd. has a market cap of $361.41M USD, ranking #17385 globally and #951 in India. It ranks #1578 in the Healthcare sector, and #568 in the Drug Manufacturers - General industry.
Global Rank
17385
Country Rank
951
Sector Rank
1578
Industry Rank
568
Key Stats
Market Cap
$361.41MUSD
34.11B INR
Enterprise Value
$419.46MUSD
39.6B INR
Revenue (TTM)
$267.18MUSD
25.22B INR
EBITDA (TTM)
$31.67MUSD
2.99B INR
Net Income (TTM)
$21.46MUSD
2.03B INR
EBITDA Margin
12%
Profit Margin
8%
PE Ratio
16.8
Forward PE
16.7
PS Ratio
1.4
PB Ratio
2.3
EV/EBITDA
13.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Prakash Patil open_in_new
Employees
1,284
Founded
1984
Website
aartidrugs.co.in open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.8% 3.2% 13% -3% -22% 6.2%

News

Loading...

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
AARTIDRUGS
Aarti Drugs Ltd
ISIN: INE767A01016
Shares Out.:
91.27M1 Shares Float: 36.368M2
TV:
SA:
YF:
GF:
BA:
MS:
376.30 INR
Bombay Stock Exchange
MIC: XBOM
524348 (AARTIDRUGS)
Aarti Drugs Ltd
ISIN: INE767A01016
TV:
SA:
YF:
GF:
BA:
MS:
373.75 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Aarti Drugs Ltd.

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Similar Companies

Industry: Drug Manufacturers - General (India)
Name
Market Cap diff.
PE
$45.22B
4.27T INR
12K%
39.1
DIVISLAB
$18.38B
1.73T INR
5K%
70.0
$15.17B
1.43T INR
4K%
63.0
$11.73B
1.11T INR
3K%
19.6
MANKIND
$9.87B
931.67B INR
3K%
52.2
ZYDUSLIFE
$9.71B
916.53B INR
3K%
18.6
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
211K%
38.1
JNJ
$547.28B
151K%
26.4
ABBV
$360.63B
100K%
97.4
$318.3B
256.25B CHF
88K%
19.9
AZN
$284.64B
215.59B GBP
79K%
27.6
MRK
$274.03B
76K%
15.1
chevron_leftBack